市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | ADC Therapeutics SA | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | -1.7 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -1.7 |
| 时机 35% | 2.6 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 2.0 |
| 技术平均移动指标 参考 | 3.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×0.85 |
| 不计入评分 | |
| 价格波动 参考 | 0.2 |
| 最终评分 | 0.21 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 21.58% |
| 机构持股比例 | 66.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 11,526,710 |
| Tcg Crossover Management, Llc | 30 Jun 2026 | 11,390,175 |
| Prosight Management, Lp | 30 Jun 2026 | 7,824,749 |
该时间范围内无数据。
该时间范围内无数据。
投资组合